What is CJC-1295?
CJC-1295 is a tetrasubstituted peptide analog of GHRH with a drug affinity complex (DAC) modification — a reactive maleimide group that forms a covalent bond with serum albumin after injection. This dramatically extends its half-life from minutes to 6–8 days, allowing once-weekly dosing with sustained GH and IGF-1 elevation. Available through compounding pharmacies with a prescription.
Mechanism of Action
GHRH receptor agonism with albumin-binding DAC modification; sustained pituitary somatotroph stimulation; elevated IGF-1 through continuous GH secretion
Target: GHRH receptor (GHRHR), serum albumin (DAC binding)
Research / educational reference. Educational research index only — not medical advice. Literature maturity is not a verdict on whether a compound works in people. Community reports are not evidence of efficacy.
Evidence at a glance
Derived · maturity-1.0Human efficacy is unproven unless an approved label or completed published efficacy program says otherwise. Counts reflect indexed literature volume/kind — never a verdict on effect.
Literature maturity
nascent 24/100
PubMed hits
33
CT.gov trials
1
Strong-human apps
0
Sample papers
7
Sample articles by era
- pre-20185
- 2018-20202
Application grades (curated)
- Human-grade apps1
- Animal / in-vitro0
- Mechanistic0
Does literature support studied applications?
Grades reflect cited literature posture — not a treatment recommendation. Community notes are never efficacy evidence.
| Application | Cited evidence | Grade | Community |
|---|---|---|---|
| GH secretion amplification (clinical pharmacology) | GHRH-analog pharmacology increases GH/IGF-1 in human studies; wellness outcomes vary by DAC vs no-DAC formulation. | Limited human | Community reports vary; not evidence of efficacy. |
Pharmacology
Mechanism of action
- •GHRH receptor agonism with albumin-binding DAC modification; sustained pituitary somatotroph stimulation; elevated IGF-1 through continuous GH secretion
- •Primary target framing: GHRH receptor (GHRHR), serum albumin (DAC binding)
Half-life
6–8 days (with DAC)
Identity & chemistry
- CAS
- 446262-90-4
- PubChem
- CID 91971820
- Formula
- C165H269N47O46
- Molar mass
- 3647.2 Da
- InChIKey
- ZUQGTWKGESAQCD-ZGFIGYLBSA-N
Identity cross-checked with PubChem where available. Compass HTML used only as a bootstrap checklist — not republished as product copy.
Storage & stability
- Lyophilized
- 2–8°C; lyophilized typical shelf 18–24 months
- Reconstituted
- 2–8°C; in-use window often 30–45 days (product-dependent)
- Tell-tale degradation
- !Cloudiness, clumping, or particles after mixing
- !Discoloration versus the expected clear/colorless (or labeled) solution
- !Failed or incomplete reconstitution of lyophilized cake
Educational estimates. Prefer product labeling and peptide shelf-life tool.
Lab handling posture
Research / educational handling notes only. Not a substitute for an SDS.
- •Use PPE appropriate for peptide powder/solution handling
- •Avoid inhalation of lyophilized powder; handle spills per institutional policy
- •Do not present research materials as medicines
Sample indexed literature
- Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults.
The Journal of clinical endocrinology and metabolism · 2006 · PMID 16352683
- Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects.
Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society · 2009 · PMID 19386527
- Netnography of Female Use of the Synthetic Growth Hormone CJC-1295: Pulses and Potions.
Substance use & misuse · 2016 · PMID 26771670
- A method for confirming CJC-1295 abuse in equine plasma samples by LC-MS/MS.
Drug testing and analysis · 2019 · PMID 30938069
- An immuno polymerase chain reaction screen for the detection of CJC-1295 and other growth-hormone-releasing hormone analogs in equine plasma.
Drug testing and analysis · 2019 · PMID 30489688
- Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse.
American journal of physiology. Endocrinology and metabolism · 2006 · PMID 16822960
Research Indications
Stimulates natural GH release through pituitary signaling pathways
Associated with increased lean mass and reduced body fat
Supports tissue repair and recovery from exercise or injury
Some protocols show improvements in slow-wave and restorative sleep
Research Protocols
These are commonly discussed research protocols — not medical advice. Consult a healthcare provider before use.
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| Pulse Dosing (no DAC) | 100 mcg | 2–3x weekly | Subcutaneous injection |
| Standard with DAC | 1 mg | Once weekly | Subcutaneous injection |
| High Dose with DAC | 2 mg | Once weekly | Subcutaneous injection |
Peptide & Drug Interactions
Always consult your healthcare provider before combining with other compounds. Use our Interaction Checker for reference.
How to Reconstitute & Inject
Use bacteriostatic (BAC) water only. Avoid saline — may cause precipitation. Refrigerate and use within 28 days.
- 1
Remove CJC-1295 vial from refrigeration and allow to reach room temperature (15–20 minutes)
- 2
Clean vial top with alcohol swab and allow to air dry completely
- 3
Using a sterile syringe, draw the calculated volume of bacteriostatic water (BAC water)
- 4
Inject BAC water slowly down the side of the vial — do not aim directly at the powder
- 5
Gently swirl in circular motions — DO NOT shake vigorously as this degrades the peptide
- 6
Allow 2–3 minutes for full dissolution — solution should be clear and colorless
- 7
Draw calculated dose into an insulin syringe for subcutaneous injection
- 8
Inject into abdomen, thigh, or upper arm. Rotate injection sites to prevent lipodystrophy
- 9
Store reconstituted solution refrigerated (2–8°C) and use within 28 days
What to Expect
Week 1–2
Improved sleep quality may begin. Mild water retention possible initially.
Week 2–4
Deeper sleep, improved recovery. Appetite may increase slightly.
Week 4–8
Noticeable improvements in body composition, energy, and recovery speed.
Week 8–12
Skin quality improvements, reduced body fat, increased lean mass becoming visible.
Week 12+
Sustained improvements in body composition, strength, and overall vitality.
Side Effects & Safety
- Water retention and mild bloating, especially early in protocol
- Increased appetite (particularly with GHRP compounds)
- Flushing or warmth at injection site
- Tingling or numbness (carpal tunnel-like symptoms at higher doses)
- Fatigue or lethargy if dosed at suboptimal times
- Cortisol and prolactin elevation possible (especially GHRP-6)
- Rare: Elevated blood glucose — monitor if diabetic or pre-diabetic
FDA Status & Regulatory Info
CJC-1295 is a tetrasubstituted peptide analog of GHRH with a drug affinity complex (DAC) modification — a reactive maleimide group that forms a covalent bond with serum albumin after injection. This dramatically extends its half-life from minutes to 6–8 days, allowing once-weekly dosing with sustained GH and IGF-1 elevation. Available through compounding pharmacies with a prescription.
Frequently Asked Questions
Research References
External links for education only. We do not control third-party content.
Community-reported data
The information below reflects self-reported experiences from PeptIQ app users. It is not clinical evidence and should not replace professional medical advice.
Community Intelligence
What 33 users report
Overall experience
From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Favorable 96% · Mixed 4% · Unfavorable overall 0%
Most reported benefits
Benefits users selected when logging a favorable or mixed check-in.
Most logged side effects
Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Self-reported dose per injection
Median bucket: 0.4–0.6 mg · Most common: 0.2–0.4 mg
Reports span 0.1–3 mg
Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.
Commonly stacked with
How repeat users are trending
Among repeat reporters, 92% said they felt similar to their last entry, 8% more positive, and 0% more negative.
Overall, repeat reporters leaned more positive than their previous entry.
Median gap between entries: 48 days · Based on 25 repeat reporters
Share Your Experience
Rate CJC-1295 in the PeptIQ app and help the community make informed decisions.
Educational information only
This page is for educational reference. It is not medical or legal advice. PeptIQ does not sell peptides or list vendors. Consult the FDA and a licensed healthcare professional for current regulations and individualized guidance.